READDI
  • About Us
    • Leadership
    • Scientific Advisory Board
  • Partners
  • Our Approach
  • Resources
    • Virtual Press Kit
    • News
  • Get Involved
    • Partner with Us
    • Contact Us
  • About Us
    • Leadership
    • Scientific Advisory Board
  • Partners
  • Our Approach
  • Resources
    • Virtual Press Kit
    • News
  • Get Involved
    • Partner with Us
    • Contact Us

News

READDI, in Collaboration with Chimerix, to Present at International Conference on Antiviral Research

2/24/2022

 
Preclinical data from the Company’s CMX521 program will be featured in a late-breaking oral presentation session at the International Conference on Antiviral Research (ICAR) on Wednesday, March 23, 2022 from 12:15 – 1:00 pm PT. CMX521 was found to significantly reduce lung viral titer and clinical symptoms in a SARS-CoV-2 mouse model.

Read More

READDI Receives $18 Million in State Appropriations

2/11/2022

 
The state funds will allow READDI to build out a small management team, including the initial hire of a CEO, who will work to create broad spectrum antiviral drugs to combat novel coronaviruses, among other viruses.

Read More

    Archives

    May 2022
    February 2022
    November 2021
    September 2021
    August 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    October 2020
    September 2020
    August 2020
    July 2020

    Categories

    All
    Covid

About Us
Leadership
Scientific Advisory Board

Partners
Our Approach
Resources
Virtual Press Kit
News Releases

Get Involved
Partner With Us
Contact Us

Picture
READDI is led by The University of North Carolina at Chapel Hill.
Get Involved
Privacy and Cookies